The Journal of Korean Medicine (대한한의학회지)

The Society of Korean Medicine (대한한의학회)
권호 표지

Effect of Banhasasim-tang on the Hepatic, Splenic and Cardiac Toxicity Induced by Doxorubicin

반하사심탕이 Doxorubicin에 의해 유발된 독성에 미치는 영향

  • 신민규 (경산대학교 한의과대학 내과학교실) ;
  • 황희정 (경산대학교 한의과대학 내과학교실) ;
  • 김상찬 (경산대학교 한의과대학 방제학교실) ;
  • 변준석 (경산대학교 한의과대학 내과학교실)
  • Published : 2003.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

The effect of Banhasasim-tang extracts on the hepatic, splenic and cardiac toxicity induced by doxorubicin administration (three injection protocol) were monitored using male ICR mice. Changes of body weight, clinical signs, necropsy findings and organ weights of liver, spleen and heart were observed with blood GOT and GPT levels. The results were as follows: 1. Decrease of body weight after doxorubicin treatment was dose-dependently inhibited by Banhasasim-tang extracts. 2. The degrees of anorexia, ataxia and dehydration that were observed in doxombicin treatment groups were dose-dependently inhibited by Banhasasim-rang extracts. 3. Increase of absolute and relative liver weight observed in the doxorubicin treatment group were dose-dependently inhibited by Banhasasim-tang extracts. In addition, the degrees of liver congestion and necrotic spot were significantly and dose-dependently decreased in the Banhasasim-rang extracts dosing group compared to that of the doxorubicin-only treatment group. It is also demonstrated that elevated serum GOT and GPT levels in the doxorubicin treatment group were significantly decreased in the Banhasasim-rang extracts dosing group. 4. Decrease of absolute and relative spleen weight observed in doxorubicin treatment groups were dose-dependently inhibited by Banhasasim-rang extracts. In addition, the degrees of splenic atrophy were significantly and dose-dependently decreased in the Banhasasim-rang extracts dosing group compared to that of doxorubicin-only treatment group. 5. Increase of absolute and relative heart weight observed in doxorubicin treatment groups were dose-dependently inhibited by Banhasasim-rang extracts. In addition, the degrees of heart congestion and enlargement were significantly and dose-dependently decreased in the Banhasasim-rang extracts dosing group compared to that of the doxorubicin-only treatment group. In conclusion, the toxicity of doxorubicin treatment (decrease of body weight, clinical signs such as anorexia, ataxia and dehydration, changes of organ weights of liver, spleen and heart, elevation of serum GOT and GPT levels) was inhibited and/or prevented by Banhasasim-rang extracts. According to these results, it is considered that Banhasasim-rang has some preventive effect against the toxicity induced by doxorubicin.

Keywords

References

  1. 최신치료위암 1 徐滿正
  2. 이우주의 약리학강의 1 홍사석
  3. Cancer Res. v.61 Attenuation of Doxorubicin chronic toxicity in metallothionein- overexpressing transgenic mouse heart Sun X;Zhou Z;Kang YJ
  4. Oncol. v.19 The anthracyclines: will we ever find a better Doxorubicin Semin Weiss RB
  5. Cancer v.60 Acute arrhythmogenicity of Doxorubicin administration Steinberg JS;Cohen AJ;Wasserman AG;Cohen P;Ross AM
  6. J. Am. Med. Assoc. v.266 Cardiac toxicity 4 to 20 years after completing anthracycline therapy Steinherz LJ;Steinherz PG;Tan CT;Heller G;Murphy ML
  7. Hum. Exp. Toxicol. v.17 Preclinical toxicology of a novekl polymeric antitumour agent. HPMA copolymer-Doxorubicin(PK1) Duncan R;Coatsworth, JK;Burtles S
  8. 암, 동서의학결합치료2 v.1 문구;정병학;김병주
  9. Pharmacol. Res. v.43 The preventive role of deferoxamine against acute Doxorubicin-induced cardiac, renal and hepatic toxicity in rats Saad SY;Najjar TA;Al-Rikabi AC
  10. In Vivo. v.7 Preclinical toxicology study of liposome encapsulated Doxorubicin(TLC D-99). comparison with Doxorubicin and empty liposome in mice and dogs Kanter PM;Bullard GA;Pilkiewicz FG;Mayer LD;Cullis PR;Pavelic ZP
  11. Eur. J. Pharmacol. v.414 Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on Doxorubicin-induced cardiotoxicity in the rat Sacco G;Bigioni M;Evangelista S;Goso C;Manzini S;Maggi CA
  12. Anticancer Drug Des. v.15 Prevention of adriamycin-induced mdrl gene amplification and expression in mouse leukemia cells by simultaneous treatment with the anti-recombinogen bromovinyl-deoxyuridine Fahrig R;Steinkamp-Zucht A;Schaefer A
  13. 傷寒論解釋 1 최달영;김준기
  14. Blood v.91 The tetrapeptide acetyl-N-Ser-Asp-Lys-Pro(Goralatide) protects from Doxorubicin-induced toxicity: improvment in mice survival and protection of bone marrow stem cells and progenitors Mass A;Ramirez, LH;Bindoula G;Grillon C;Wdzieczalk-Bakala J;Raddassi K.(etc.)
  15. 임상검사법제요 1 고문사 편집부
  16. 해리슨내과학 13 해리슨 내과학 편찬위원회
  17. Crit. Rev. Oncol. Hematol. v.37 Caelyx(stealyh lipomal Doxorubicin) in the treatment of advanced breast cancer Ranson MR;Cheeseman S;White S;Maqrgison J
  18. Anticancer Drugs v.11 The exo vivo effect of high concentration of Doxorubicin on recurrent ovarian carcinoma Neale MH;Lamont A;Hindley A;Kurbacher CM;Cree IA
  19. Ann. Intern. Med. v.91 Risk factors for Doxorubicin-induced congestive heart failure Von Hoff DD;Layard MW;Basa P;Davis HL. Jr;Von Hoff AL;Rozencweig M.(etc.)
  20. 半夏瀉心湯의 效能에 관한 실험적 연구 朴治洙
  21. 半夏瀉心湯과 cimetidine의 병용투여가 흰쥐의 위궤양에 미치는 영향 복진우
  22. 半夏瀉心湯 및 半夏瀉心湯加赤石脂가 實驗的 胃潰瘍에 미치는 영향 조남수
  23. 本草學 3 全國韓醫科大學 本草學敎室
  24. 방제학 2 李尙仁;金東傑;金永坂;盧昇鉉;朴宣東;李暎鍾;周榮丞
  25. Cancer Chermother. Pharmacol. v.45 Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of Doxorubicin in spontaneously hypertensive rats Herman EH;Zhang J;Chadwick DP;Ferrans VJ
  26. Eur. J. Cancer Clin. Oncol. v.23 Exogenous Doxorubicinol induces cardiotoxic effects in the rats Danesi R;de Tacca M;Bernardini C;Penco S
  27. Tumori. v.86 Modulatory effects of melatonin and vitamine E on doxorubicin-induced cardiotoxicity in Ehrlich ascites carcinoma-bearing mice Wahab MH;Akoul ES;Abdel-Aziz AA
  28. In Vivo. v.8 Preclinical toxicology study of liposome encapsulated Doxorubicin(TLC D-99) given intraperitoneally to dogs Kanter PM;Klaich G;Bullard GA;King JM;Pavelic ZP
  29. Toxicol. Sci. v.60 Single-dosed toxicity study of hepatic intra-arterial infusion of Doxorubicin coupled to a novel magnetically targeted drug carrier Goodwin SC;Bittner CA;Peterson CL;Wong G
  30. Cancer Res. v.47 Effect of allyl alcohol-induced sublethal hepatic damage upon Doxorubicin metabolism and toxicity in the rabbit Brenner DE;Anthony LB;Halter S;Harris NL;Collins JC;Hande KR.(etc.)
  31. J.A.M.A. v.256 Subclinical hepatic toxicity during combination chemotherapy for breast cancer Larroquette CA;Hortobagyi GN;Buzdar AU;Holmes FA
  32. Small animal clinical diagnosis by laboratory methods 1 Willard MD
  33. Phytomedicine v.7 Treatment of chemotherapy-induced leukopenia in a rat model with aqueous extract from Uncaria tomentosa Sheng Y;Pero RW;Wagner H
  34. Toxicol. Pathol. v.22 BR96-Doxorubicin conjugate(BMS-182248) versus Doxorubicin: a comparative toxicity assessment in rats Comereski CR;Peden WM;Davidson TJ;Warner GL;Hirth RS;Frantz JD
  35. Eur. J. Cancer v.30 no.A Increased bone marrow toxicity of Doxorubicin bound to nanoparticles Gibaud S;Andreux JP;Weingarten C;Renard M;Couvreur P
  36. Pharmacol. Toxicol. v.88 Role of daunorubicinol in daunorubicin-induced cardiotoxicity as evaluated with the model of isolated perfused rat heart Platel D;Bonoron-Adele S;Robert J
  37. Eur. J. Cancer v.37 Modification of Doxorubicin-induced cardiotoxicity. effect of essential fatty acids and ICRF-187(dexrazoxane) Chakrabarti KB;Hpewell JW;Wilding D;Plowman PN
  38. Am. J. Physiol. Regul. Integr. Com. Physiol. A novel pharmacological action of ET-1 to prevent the cytotoxicity of Doxorubicin in cardiomyocytes Suzuki T;Miyauchi T
  39. J. Biol. Chem. v.275 Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species Kotamraju S;Konorev EA;Joseph J;Kalyanaraman B